Email Updates

You are here

AVAC in the News

  • The dark days of the HIV pandemic are over, but patients still face social stigma and emotional distress that can push them to stop treatment or even into a deep depression. Hear it first-hand from people who’ve experienced it.

    November 30, 2020
    General
    Bhekisisa
  • Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure were identified. Using a process of expert face-to-face consultation and an online Delphi consultation, we found a high degree of agreement regarding the criteria for the optimum target product profile. Although the minimum attributes for a cure were debated, the broad consensus was that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy.

    November 30, 2020
    Lancet HIV
  • We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.

    November 30, 2020
    Lancet HIV
  • Each week, good news about vaccines or antibody treatments surfaces, offering hope that an end to the pandemic is at hand. And yet this holiday season presents a grim reckoning. The United States has reached an appalling milestone: more than one million new coronavirus cases every week. Hospitals in some states are full to bursting. The number of deaths is rising and seems on track to easily surpass the 2,200-a-day average in the spring, when the pandemic was concentrated in the New York metropolitan area.

    November 30, 2020
    General
    New York Times
  • The message is simple to understand. An undetectable viral load in people living with HIV equals an untransmissible virus. The success of this concept, however, depends on strict adherence to antiretroviral therapy (ART).

    November 24, 2020
    Spotlight
  • The news last week and again this week that at least two highly effective vaccines may be on the horizon is a welcome respite from the devastating impact of COVID-19 on global health. In under a year, SARS-CoV-2 has already caused more than 56 million infections and 1.3 million deaths.

    November 19, 2020
    General
    Devex
  • Six shots a year of an antiretroviral (ARV) drug can protect women from contracting HIV, new research shows. Activists say although the jab won’t be available immediately, countries need to start doing the planning—and the math—to introduce the bimonthly injection now.

    November 16, 2020
    Mail & Guardian
  • Researchers are stopping a study early after finding that a shot of an experimental medicine every two months worked better than daily pills to help keep women from catching HIV from an infected sex partner.

    November 9, 2020
    Washington Post
  • Even if a jab is shown to work, there won’t be enough doses for everyone. Countries such as South Africa would need to make tough decisions about who it would give the vaccine to — and more importantly how to create a system to get it to them.

    October 14, 2020
    General
    Bhekisisa
  • Experts have called on the federal government and other stakeholders to invest more in efforts to prevent HIV infection human immunodeficiency virus, HIV prevention interventions while advocating for supportive policy and programmes.

    October 13, 2020
    Vanguard

Pages